Progressive muscle relaxation technique in the care of anxiety and pain in the cancer patient

Is the muscle relaxation technique capable of improving the quality of life of cancer patients with anxiety and pain?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN81335752

Enrollment

272

Registered

2016-11-22

Start date

2014-11-01

Completion date

Unknown

Last updated

2018-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, pain and nausea in cancer patients Signs and Symptoms Anxiety, pain and nausea in cancer patients

Interventions

All participants receive a guided session in order to learn abbreviated progressive muscle relaxation training by following Bernstein and Borkovec. These sessions are conducted individually or in grou

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 18 years and over 2. Cancer patients 3. Experiencing anxiety, muscle tension, sleeping difficulties, sadness, or anxiety attacks 4. Provision of consent to participate

Exclusion criteria

Exclusion criteria: Patients suffering from hallucinations, delirium or other psychotic symptoms.

Design outcomes

Primary

Measure	Time frame
1. Quality of life is measured using the FACT-G (Functional Assessment of Cancer Therapy - General) questionnaire at baseline and weekly for four weeks (1 month) 2. Anxiety is measured using a visual analogue scale (VAS) at baseline and weekly for four weeks (1 month) 3. Pain is measured using a visual analogue scale (VAS) at baseline and weekly for four weeks (1 month) 4. Nausea is measured by asking participants a yes/no question about their nausea levels at baseline and weekly for four weeks (1 month)	—

Measure

Time frame

1. Quality of life is measured using the FACT-G (Functional Assessment of Cancer Therapy - General) questionnaire at baseline and weekly for four weeks (1 month) 2. Anxiety is measured using a visual analogue scale (VAS) at baseline and weekly for four weeks (1 month) 3. Pain is measured using a visual analogue scale (VAS) at baseline and weekly for four weeks (1 month) 4. Nausea is measured by asking participants a yes/no question about their nausea levels at baseline and weekly for four weeks (1 month)

—

Secondary

Measure	Time frame
1. Analgesic use is measured through patient interviews at baseline and weekly for four weeks (1 month) 2. Anxiolytic use is measured through patient interviews at baseline and weekly for four weeks (1 month) 3. Hypnotics use is measured through patient interviews at baseline and weekly for four weeks (1 month) 4. Antidepressant use is measured through patient interviews at baseline and weekly for four weeks (1 month)	—

Measure

Time frame

1. Analgesic use is measured through patient interviews at baseline and weekly for four weeks (1 month) 2. Anxiolytic use is measured through patient interviews at baseline and weekly for four weeks (1 month) 3. Hypnotics use is measured through patient interviews at baseline and weekly for four weeks (1 month) 4. Antidepressant use is measured through patient interviews at baseline and weekly for four weeks (1 month)

—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 6, 2026